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Porous-wall hollow glass microspheres (PW-HGMs) show promise for drug delivery applications. They are a novel ceramic 
biocompatible material with a hollow central cavity surrounded by a thin mesoporous shell. The central cavity can be loaded with 
a high concentration of a soluble biological therapeutic, for example a small RNA, protein, or antibody fragment. The thin silica 
shell protects the contents from environmental conditions. Nanometer-scale channels penetrate the shell, providing for controlled 
uptake and release of the protected material from the central cavity. We have developed a gating strategy that potentially allows 
the pores to be opened and closed. The hollow interior, protective walls, and gated, controlled-porosity channels distinguish the 
technology from competing drug delivery approaches. 
Introduction 
Conventional drug delivery relies on oral ingestion or injection. 
These methods do not allow delivery to specific anatomic sites. 
In addition, macromolecular drugs (peptides, proteins, 
antibodies, DNA, and RNA) are often poor candidates for 
delivery by these routes due to their instability, limited tissue 
penetration, or rapid turnover. The global drug market has 
witnessed a significant growth in development of 
macromolecular drugs, yet delivery remains a limiting factor. 
 Bioactive glass materials, or composites of bioactive glass 
and polymers, have shown promise as carriers for both small 
molecules and protein therapeutics, such as vascular 
endothelial growth factor and bone morphogenetic proteins [1-
5]. Glass materials have also been developed as a therapeutic 
radiation delivery system [6-8]. 
 Currently, use of glass materials for delivery of therapeutic 
agents requires either bonding to organic polymers or the 
deposition of chemical substances directly into the glass 
matrix. We recently described a more general approach for 
drug delivery using glass materials [9]. The approach is based 
on porous-wall hollow glass microspheres (PW-HGMs), which 
are micron-scale glass “balloons” with an internal cavity 
bounded by a 1 µm-thick mesoporous wall [10]. PW-HGMs are 
generally fabricated in sizes ranging from 10 to 100 µm. The 
hollow central cavity can be loaded with a high concentration 
of a soluble biological therapeutic, for example a small RNA, 
protein, or antibody fragment. In addition, the walls are 
characterized by worm-like, interconnected channels in a 
silica-rich matrix [10]. Together, these characteristics allow 
them to function as carriers for diverse materials.  
 We hypothesized that PW-HGMs might be useful for 
controlled delivery of macromolecular therapeutics. We 
therefore tested their ability to interact with proteins, 
carbohydrates, and nucleic acids [12] In this chapter, we 
summarize the results of our studies. These results suggest that 
PW-HGMs may be useful as a controlled release delivery 
vehicle for both protein and oligonucleotide therapeutics. 
Materials and Methods 
Fabrication of PW-HGMs 
Details of the process have been described elsewhere, along 
with methodologies for loading or filling these materials [11-
14]. Briefly, the feed for producing PW-HGMs was a 20-40 µm 
sodium borosilicate glass powder, similar to commercial 
Vycor, and containing a sulfate blowing agent. The powder was 
fed into a hot zone produced by a controlled gas-air flame, 
which softens the glass to allow formation of spherical 
particles. The material was quenched, and a flotation process 
was used to retrieve the desired initial products. These were 
heat-treated to produce two phases in the thin outer walls, one 
rich in silica and the other in sodium and boron.  The hollow 
microspheres were treated with 4 M HCl, which preferentially 
leaches the sodium and boron-rich phase, leaving 
interconnected channels in the silica-rich phase.  
Fluorescently-labeled biopolymers 
Fluorescein-labeled dextrans were obtained from Sigma-
Aldrich (St. Louis, MO). A 55 base pair 5’-Alex Fluor 546-
labeled oligonucleotide was prepared as described [9]. Cy 3-
labeled GAPDH siRNA was from Applied Biosystems (Austin, 
TX). Alexa Fluor 594-labeled goat anti-rabbit IgG was 
obtained from Invitrogen. 
 
Biopolymer loading 
 Dry PW-HGMs (2-3 mg) were suspended in 50-100 µl of 
PBS containing 200 µg/ml of biopolymer and incubated at 
room temperature for 5-10 min. A portion was used for direct 
observation, and the remainder was collected by gentle 
centrifugation, washed with 0.5 ml of PBS or fetal bovine 
serum, and centrifuged again. The pellet was resuspended in 
50-100  µl of PBS or fetal bovine serum for imaging. 
Microscopy was performed using a Zeiss LSM 510 laser 
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scanning confocal microscope with a 40X or a 63X oil 
objective or an Applied Precision Deltavision microscope with 
a 20X or a 60X oil objective.  
Mouse imaging 
Animal experiments were performed at the Medical College of 
Georgia according to an Institutional Animal Care and Use 
Committee-approved protocol. PW-HGMs (3.3 mg) were 
incubated with fluorescein-labeled 70 kDa dextran (200 µg/ml) 
in 100 µl PBS. Just before use, PW-HGMs were washed twice 
with PBS and resuspended in 500 µL of PBS. Fluorescence 
images were collected using a Xenogen IVIS Imaging System 
equipped with 445-490 nm bandpass filter for excitation and a 
515-575 nm bandpass filter for emissions. Images were 
acquired with a 1 s exposure, and LivingImage 2.60 Software 
was used to perform a fluorescent overlay, which allowed the 
subtraction of background to produce the final images. 
Results and Discussion 
Interaction of PW-HGMs with biological macromolecules 
The diameters of PW-HGMs ranged from 10 to 100 µm. with a 
typical wall thickness of 1 µm (Fig. 1A). Scanning electron 
microscopy (not shown, see ref. [9]) reveals the presence of 
ink-bottle shaped pores in the outer shell, with diameters 
ranging from about 10 nm, at the narrowest point, to about 300 
nm. These pores, which connect the exterior space with the 
interior volume of the microspheres, are the distinguishing 
characteristic of PW-HGMs. 
 To investigate the ability of biological polymers to penetrate 
the interior volume of the PW-HGMs, we performed 
experiments using fluorescently-labeled dextrans, proteins, and 
nucleic acids. A 500 kDa dextran, with an estimated diameter 
of about 14.4 nm, failed to enter the microspheres (Fig. 1B), 
whereas a smaller, 70 kDa dextran, with an estimated diameter 
of 6.0 nm, freely equilibrated with the interior volume. Results 
with these and other dextrans [9] suggest that the porous walls 
behave as molecular sieves, passing the smaller dextrans and 
excluding the larger.  
 Interestingly, the 70 kDa dextran accumulated in the 
microsphere walls to levels exceeding its concentration in 
solution, a behavior not seen with any of the larger or smaller 
dextrans (Fig. 1B and data not shown, see ref [9]). The 70 kDa 
dextran is about the same size as the diameter of the pores 
themselves, and we hypothesize that it is of a critical size that 
allows a large fraction of its surface area to contact the wall 
material at any given time, stabilizing its interaction.  
 A fluorescently-labeled Immunoglobulin G (IgG), which is 
about the same size as the 70 kDa dextran (5.3 nm) behaved 
similarly, with concentration and retention in the microsphere 
walls. By contrast, several smaller proteins, including 
ovalbumin, carbonic anhydrase, and RNase A, entered the PW-
HGMs freely but showed little retention after washing (data not 
shown, see ref [9]). We suggest that they are too small to make 
a sufficient number of contacts with the walls of the pores, 
accounting for poor retention. 
 We also explored the interactions of PW-HGMs with nucleic 
acids. A double-stranded 55-mer DNA behaved much like the 
smaller dextrans and proteins, freely entering and exiting the 
interior volume, with some retention within the porous walls 
after washing (data not shown, see ref [9]). A double-stranded 
21-mer small interfering RNA (siRNA) behaved similarly to 
the DNA, freely equilibrating between the exterior medium and 
the interior cavity (Fig. 1B). 
 SiRNAs are of particular interest because they are in 
widespread development as therapeutic agents. Efficient 
delivery methods are the limiting factor in many applications 
(reviewed in [15,16]). Based on the idea that the 70 kDa 
dextran was about the same size as the diameter of the pores, 
we investigated whether it could be used to “gate” them in 
order to control the uptake or release of nucleic acid cargo. We 
loaded the PW-HGMs with red fluorescently-labeled siRNA, 
then incubated with green fluorescently-labeled 70 kDa 
dextran. Prior to washing, the RNA was seen inside the PW-
HGMs, and the dextran was enriched within the walls (Fig. 
1B). After washing, some PW-HGMs retained the siRNA 
(although it leached out of others) (Fig. 1B).  We performed 
time-lapse studies of release of siRNA from individual PW-
HGMs (data not shown, see ref [9]). The signal density for 
siRNA was bright initially and declined with time. These 
results suggest that, in principle, PW-HGMs may be useful as a 
controlled release delivery vehicle for siRNA. 
Visualization of PW-HGMs in vivo  
The PW-HGMs are considerably larger than blood cells and are 
thus too large for systemic administration by an intravenous 
route. We envision their use in applications, such as tumor 
embolization or tissue regeneration, where there is a need to 
retain the therapeutic molecules at a localized site. In this 
application, it would be ideal to be able to visualize the initial 
placement of the PW-HGMs and their retention at the desired 
site.  
 As a first step toward determining whether PW-HGMs could 
 
Fig.1 Interaction of PW-
HGMs with biological 
macromolecules. A. Single 
optical sections, differential 
interference contrast. Low 
power (left) and high power 
(right) images are shown. 
Scale bar at right, 10 µm. B. 
Single optical sections of 
PW-HGMs incubated with 
indicated compounds and 
imaged prior to washing (left 
column) or after washing 
(right column). Bottom 
panels show sequential 
incubation with siRNA, then 
70 kDa FITC-Dextran. All 
panels same magnification, 
scale bar, 10 µm. Note 
retention of siRNA by FITC-
dextran-gated PH-HGMs. 
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be visualized in vivo, we tested the ability to detect them using 
a standard small-animal imaging system. We loaded PW-
HGMs with fluorescently-labeled 70 kDa dextran, transferred 
them to microcentrifuge tube, and performed imaging as 
described in Materials and Methods. The method proved to be 
very sensitive, as evidenced by the ability to detect even very 
small droplets of PW-HGM slurry on the walls of the tube  
(Fig. 2A, 2B). Quantitative image analysis, reported elsewhere, 
reveals a linear relationship between the amount of material 
loaded and the corresponding photon counts [9]. We also 
injected of the same PW-HGMs into the liver of an 
anesthetized, laparotomized mouse. The image shows clear 
localization at the site of injection (Fig. 2C), with some signal 
also around the periphery of the liver, possibly following 
leakage along the injection track. In experiments elsewhere, we 
have also shown the ability to detect PW-HGMs in situ 
following intratumoral injection [9]. 
Conclusions 
 The results suggest that PW-HGMs may be useful for delivery 
of macromolecular therapeutics. Interaction of biomolecules is 
strongly size dependent, and there are several examples of 
molecules of a critical size that interact strongly with the 
porous walls. In the case of 70 kDa dextran, we show that this 
molecule can actually be used to gate the pores, so as to obtain 
controlled release of a small RNA from the interior volume. 
We show also that it is possible to visualize the initial 
placement of PW-HGMs in vivo using standard small animal 
imaging approaches.  
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Fig. 2 Beads were incubated with 70 kDa FITC-dextran and washed 
as in Figure 1. A. White light image. B. Fluorescence image of 
same tube. C. Visualization in a mouse. Mouse was anesthetized, 
laparotomized, liver was injected with 10, 30, and 50 µl boluses of 
beads, and mouse was immediately imaged for green fluorescence. 
Arrowhead denotes signal at injection site. Note also signal around 
periphery of liver, possibly following leakage along injection track. 
